DNDN

Dendreon Bankruptcy: DNDN Files for Chapter 11

By William White, InvestorPlace Writer
Dendreon, a biotech company that created the prostate-cancer drug Provenge, has filed for Chapter 11 bankruptcy protection.

Dendreon Earnings Suck, But Still Send DNDN Stock Higher

By James Brumley, InvestorPlace Feature Writer
Dendreon shareholders don't have any more to worry about after Q3's numbers were posted, but they don't have any less to worry about with their DNDN trade either.

Stocks Get Another Fed Jolt: Tuesday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Wall Street got a little oomph from Atlanta Federal Reserve chief comments indicating that September tapering wasn't a foregone conclusion.

Dendreon Looks Like a Buy After Meltdown

By James Brumley, InvestorPlace Feature Writer
The Dendreon rags-to-riches-to-rags story saga has a light at the end of the tunnel, but can also teach investors a few valuable big-picture lessons.

Slow Your Roll, Wall Street: Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
A positive reading in U.S. manufacturing wasn't enough to help out the broader markets, though Tyson and Facebook were among some individual standouts.

Changing U.S. Demographics Mean a Decades-Long Healthcare Boom

By Jeff Reeves
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.

5 Biotechnology Stocks to Sell Now

By Portfolio Grader
The overall ratings of five Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Surprise! Dendreon Doesn’t Stink Anymore

By James Brumley, InvestorPlace Feature Writer
It took three years, but this biotech may be quietly finding its footing as its innovative Provenge prostate-cancer fighter gains credibility.

S&P Hits Five-Year High — Thursday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Positive earnings news, big corporate headlines and solid China exports helped move markets north and launched the S&P to five-year highs.

Stocks Pop to Open 2013 — Wednesday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
A deal averting the fiscal cliff sent stocks on a large, broad rally, including a 30-for-30 day for the Dow Jones Industrial Average

Not Enough Spark From ‘Merger Monday’ — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Wall Street saw three big deals in the mergers & acquisition world Monday, but the markets mostly shrugged with a flat performance.

Nothing Left to Do but Vote — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Stocks traded slightly higher on the day, led mostly by a rise in Apple, though many investors shied off big moves before tomorrow's presidential election.

Inflation and Stocks Stay Flat: Wednesday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Retail stocks continued to flourish as markets moved around during the day before ending mixed

9 Biotech Buyout Players to Watch

By Jeff Reeves
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.

Rallying on Stimulus Hopes: Thursday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Will higher jobless claims and scant inflation mean QE3? Investors are counting on the Fed to make more moves.

Great Day for Dividends! — Wednesday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Dividend news out of Dell, Target and Caterpillar wasn't enough to overcome broader macroeconomic news Wednesday, and the indices headed south.

Cue the Biotech M&A Attack!

By Gene Marcial, InvestorPlace Contributor
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Price targets keep climbing to the moon: $715, $910 -- even $1,001.

Investors Bid Up Homebuilders, Energy Stocks — Monday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
A rise in pending home sales lifts equities to a flat day overall. Lowe's joins the homebuilders' rise for the day.
Load More